ITGB2 and leukocyte adhesion deficiency 1: A clinical trial in which CD34+-enriched hematopoietic stem cells from subjects with severe LAD-I were transduced ex vivo with a lentiviral vector carrying the normal ITGB2 gene revealed the safety and efficacy of the procedure (https://clinicaltrials.gov/study/NCT03812263).